DORILLO, ERICA
 Distribuzione geografica
Continente #
NA - Nord America 424
EU - Europa 388
AS - Asia 99
AF - Africa 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 916
Nazione #
US - Stati Uniti d'America 423
IT - Italia 155
IE - Irlanda 128
HK - Hong Kong 56
RO - Romania 28
VN - Vietnam 24
CN - Cina 15
DE - Germania 15
SE - Svezia 14
FI - Finlandia 13
RU - Federazione Russa 10
UA - Ucraina 9
AT - Austria 4
BE - Belgio 4
CI - Costa d'Avorio 4
FR - Francia 4
CH - Svizzera 2
NL - Olanda 2
CA - Canada 1
EU - Europa 1
JP - Giappone 1
KH - Cambogia 1
SG - Singapore 1
UZ - Uzbekistan 1
Totale 916
Città #
Chandler 147
Dublin 128
Perugia 68
Hong Kong 56
San Mateo 51
Bucharest 28
Dong Ket 24
Altamura 19
Medford 15
Wilmington 14
Princeton 13
Lawrence 12
New York 12
Helsinki 11
Andover 10
Assisi 9
Beijing 7
Falls Church 5
San Paolo di Civitate 5
Abidjan 4
Bastia 4
Brussels 4
Collazzone 4
Dearborn 4
Foligno 4
Los Angeles 4
Rome 4
Vienna 4
Guangzhou 3
Redwood City 3
Amsterdam 2
Ancona 2
Ashburn 2
Bologna 2
Frankfurt Am Main 2
Macerata 2
Melissa 2
Moscow 2
Norwalk 2
Redmond 2
West Jordan 2
Ann Arbor 1
Baotou 1
Cambridge 1
Civitanova Marche 1
Fairfield 1
Fremont 1
Hanover 1
Jinan 1
Lappeenranta 1
Montréal 1
Nanjing 1
Paris 1
Quattro Castella 1
Spello 1
Tokyo 1
Totale 713
Nome #
Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia 120
The NOTCH1/CD39 axis: A Treg trip-switch for GvHD 72
NOTCH1 Activation Negatively Impacts on Chronic Lymphocytic Leukemia Outcome and Is Not Correlated to the NOTCH1 and IGHV Mutational Status 66
NOTCH1 Aberrations in Chronic Lymphocytic Leukemia. 65
NOTCH1 Is Aberrantly Activated in Chronic Lymphocytic Leukemia Hematopoietic Stem Cells. 65
Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia 62
NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications 57
Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome 56
NOTCH1 inhibition prevents GvHD and maintains GvL effect in murine models 53
IN VITRO AND IN VIVO ANTILEUKEMIC ACTIVITY OF BEPRIDIL IN CHRONIC LYMPHOCYTIC LEUKEMIA IS ASSOCIATED WITH INHIBITION OF THE NOTCH1 PATHWAY 48
Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML 47
null 37
BEPRIDIL IS A POTENT NOTCH1 INHIBITOR AND EFFICIENTLY INDUCES APOPTOSIS IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) CELLS in vitro AND in vivo 35
CURCUMIN EXHIBITS IN VITRO AND IN VIVO ANTI-LEUKEMIC ACTIVITY INTERFERING WITH THE NOTCH1 PATHWAY AND INDUCING ENDOPLASMIC RETICULUM STRESS IN CHRONIC LYMPHOCYTIC LEUKEMIA 29
Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia 29
Immune correlates of protection by vaccine against SARS-CoV-2 in patients with chronic lymphocytic leukaemia 27
NOTCH-1 ACTIVATION AND SUBCLONAL MUTATION NEGATIVELY IMPACT ON CHRONIC LYMPHOCYTIC LEUKEMIA OUTCOMES 26
A NOVEL MECHANISM FOR NOTCH1 ACTIVATIONIN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS: INVOLVEMENT OF NOTCH1 ENDOSOMAL TRAFFICKING AND ALTERATIONS IN RAB PROTEINS 23
NOTCH1 Aberrant Activation Is a Common Nonmutational Early Event in Chronic Lymphocytic Leukemia Hematopoietic Stem-Cells 20
GSK3β is a critical, druggable component of the network regulating the active NOTCH1 protein and cell viability in CLL 19
Therapeutic Targeting Potential of Novel Silver Nanoparticles Coated with Anti-CD20 Antibody against Chronic Lymphocytic Leukemia 13
FLT3-targeted therapy restores GATA1 pathway function in NPM1/FLT3-ITD mutated acute myeloid leukaemia 7
NOTCH1-mutated chronic lymphocytic leukemia displays high endoplasmic reticulum stress response with druggable potential 6
Totale 982
Categoria #
all - tutte 4.342
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.342


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20196 0 0 0 0 0 0 0 0 0 0 6 0
2019/202041 0 0 0 0 0 4 4 2 4 25 2 0
2020/202160 0 0 0 0 19 2 2 2 7 0 0 28
2021/2022240 12 49 3 2 9 4 3 34 11 31 37 45
2022/2023408 14 65 0 57 44 27 11 21 146 1 15 7
2023/2024166 8 25 11 15 2 13 69 1 11 10 1 0
Totale 982